Megakaryocytic proteomic signatures define myeloproliferative neoplasms

Deep visual proteomics of in situ megakaryocytes shows that bone marrow megakaryocyte proteomes from 60 Philadelphia-negative MPN patients differ from 20 control patients, with each MPN subtype having distinct signatures.

• Why it matters: Megakaryocyte niche dysregulation is implicated in these clonal stem cell disorders, but limited megakaryocyte availability in aspirates has constrained clinical proteomic profiling.
• What they did: The study used an unbiased, deep visual proteomics approach to dissect and analyze megakaryocytes from bone marrow of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis, compared with uninvolved marrow from limited-stage non-Hodgkin lymphoma controls.
• The result: Megakaryocyte proteomic profiles are distinct between MPN and control samples, and disease-specific megakaryocyte proteomes for PV, ET, and PMF highlight novel pathways linked to each condition.

AI summary of the abstract · may contain errors · not medical advice · read the paper.